Related references
Note: Only part of the references are listed.Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
Yeming Wang et al.
LANCET (2020)
Remdesivir for the Treatment of Covid-19-Final Report
John H. Beigel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Interventions for treatment of COVID-19: A living systematic review with meta-analyses and trial sequential analyses (The LIVING Project)
Sophie Juul et al.
PLOS MEDICINE (2020)
It is time for computable evidence synthesis: The COVID-19 Knowledge Accelerator initiative
Brian S. Alper et al.
JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION (2020)
RoB 2: a revised tool for assessing risk of bias in randomised trials
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2019)
PROBAST: A Tool to Assess the Risk of Bias and Applicability of Prediction Model Studies
Robert F. Wolff et al.
ANNALS OF INTERNAL MEDICINE (2019)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Jonathan A. C. Sterne et al.
BMJ-BRITISH MEDICAL JOURNAL (2016)
Assessing Bias in Studies of Prognostic Factors
Jill A. Hayden et al.
ANNALS OF INTERNAL MEDICINE (2013)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
GRADE:: an emerging consensus on rating quality of evidence and strength of recommendations
Gordon H. Guyatt et al.
BRITISH MEDICAL JOURNAL (2008)
Share Paper
